Search results
Results from the WOW.Com Content Network
FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
SVP, Finance and CFO of Fibrogen Inc (30-Year Financial, Insider Trades) Pat Cotroneo (insider trades) sold 15,004 shares of FGEN on 09/03/2020 at an average price of $50.91 a share.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Kadant Inc. is a company that was established in 1991, as a partly privately owned subsidiary of Thermo Electron, and partly publicly traded company, and was fully spun out and renamed Kadant in 2001. The company supports papermaking, paper recycling, wood processing, material handling, and other processing industries. Kadant is a multi ...
For premium support please call: 800-290-4726 more ways to reach us
Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth [8] and also is considered to cause pulmonary hypertension. [9] In phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients.